Last update Jan. 4, 2024
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lisuride Maleate, Lysuride is also known as
Lisuride Maleate, Lysuride in other languages or writings:
Lisuride Maleate, Lysuride belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 10 - 22 | % |
Molecular weight | 455 | daltons |
Protein Binding | 66 | % |
pKa | 15.36 | - |
Tmax | 1 | hours |
T½ | 2.2 - 10 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a ergot derivative, dopamine D2-agonist, with actions and uses similar to those of bromocriptine. It is used in the treatment of Parkinson's disease and hyperprolactinemia. It has been used for suppression of physiological lactation (Sénat 2016). Oral administration.
Since the last update we have not found published data on its excretion in breastmilk.
Lisuride lowers prolactin levels and suppresses lactation. (Sénat 2016, Van Dam 1981)
The risk on breastfeeding would be due to its ability for suppression of milk production, but not to a possible effect on the infant which is considered very unlikely.
If Lisuride was eventually administered to suppress lactation but afterwards the mother is willing to resuming breastfeeding, the mother can do it immediately, trying to minimize the drug effect by frequent suckling the child to stimulate milk production.
There is no evidence that pharmacological treatments are more effective than no treatment in suppressing lactation in the first week postpartum. Expert authors and professional consensus contraindicate pharmacological treatment to suppress lactation. (Marcellin 2015, Sénat 2015, Prescrire 2013, Oladapo 2012)
See below the information of this related product: